TRIC, a Novel Modulator of Intracellular Ca Homeostasis

TRIC,一种新型细胞内 Ca 稳态调节剂

基本信息

  • 批准号:
    8223258
  • 负责人:
  • 金额:
    $ 7.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-03-15 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A fundamental aspect of cellular signaling is the release of Ca from sequestered intracellular stores in the sarcoplasmic reticulum (SR) or endoplasmic reticulum (ER). For efficient operation of excitation-contraction coupling in muscle cells, or excitation-secretion coupling in non-muscle cells, counter ion movement across the SR or ER membrane must accompany the rapid efflux of Ca to neutralize the transient negative potential produced during Ca release. Although channels selective for monovalent cations have been reported in SR or ER membranes, no gene has been identified that encodes a SR or ER localized cation selective channel. We have recently discovered a novel gene encoding a trimeric intracellular cation-selective channel (TRIC) that contains an intracellular membrane-retention sequence at the carboxyl-terminus and a conserved leucine-zipper motif at the amino-terminus. Purified TRIC protein can form a cation-selective channel in lipid bilayer membrane, providing the possibility that TRIC may provide certain aspects of the counter-ion movement mechanism during the acute phase of Ca release. Biochemical studies identify a functional interaction between TRIC and SERCA, which may influence Ca homeostasis inside the SR. The focus of this project is to define the cellular and molecular functions of TRIC as a counter-ion channel in regulating the permeability of SR membrane to monovalent cations and/or as a modulator of Ca transport across the SR membrane. We will first establish the single channel properties of TRIC using the lipid bilayer reconstitution system. Through biochemical and molecular assays, we will identify the interacting partners for TRIC that may participate in regulating the channel activity of TRIC, or in modulating the functional interaction between TRIC and SERCA in skeletal muscle. Through comparative studies between wild type control and mutant muscle fibers lacking TRIC, we will define the physiological role of TRIC in mediating both the acute phase of Ca release from the SR and active Ca uptake into the SR. As TRIC represents a novel class of cation channels targeted to an intracellular organelle, knowledge of the role of this protein in muscle physiology will provide us valuable insights into the regulation of Ca signaling in muscle-related diseases, and in other diseases where dysfunctional Ca regulation results in pathology, such as neurodegenerative disorders.
描述(由申请人提供):细胞信号传导的一个基本方面是从肌浆网(SR)或内质网(ER)中隔离的细胞内储存中释放Ca。为了在肌肉细胞中的兴奋-收缩偶联或在非肌肉细胞中的兴奋-分泌偶联的有效操作,穿过SR或ER膜的反离子运动必须伴随Ca的快速流出以中和在Ca释放期间产生的瞬时负电位。尽管在SR或ER膜中已经报道了对单价阳离子具有选择性的通道,但是还没有鉴定出编码SR或ER定位的阳离子选择性通道的基因。我们最近发现了一个新的基因编码的三聚体细胞内阳离子选择性通道(TRIC),其中包含一个细胞内膜保留序列的羧基端和一个保守的亮氨酸拉链基序的氨基端。纯化的TRIC蛋白可以在脂质双层膜中形成阳离子选择性通道,这提供了TRIC可能在Ca释放的急性期提供反离子运动机制的某些方面的可能性。生物化学研究确定TRIC和SERCA之间的功能相互作用,这可能会影响SR内的Ca稳态。本项目的重点是定义TRIC的细胞和分子功能,作为一个反离子通道,调节SR膜对一价阳离子的渗透性和/或作为跨SR膜的Ca转运的调节剂。我们将首先使用脂质双层重构系统建立TRIC的单通道特性。通过生物化学和分子检测,我们将确定TRIC的相互作用伙伴,可能参与调节TRIC的通道活性,或在调节TRIC和骨骼肌中的SERCA之间的功能相互作用。通过野生型对照和缺乏TRIC的突变肌纤维之间的比较研究,我们将确定TRIC在介导SR的Ca释放的急性期和SR的活性Ca摄取中的生理作用。由于TRIC代表一类靶向细胞内细胞器的新型阳离子通道,了解这种蛋白质在肌肉生理学中的作用将为我们提供对肌肉相关疾病中Ca信号传导调节的有价值的见解,以及在功能失调的Ca调节导致病理学的其它疾病中,例如神经变性疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jianjie Ma其他文献

Jianjie Ma的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jianjie Ma', 18)}}的其他基金

Multifaceted role of MG53 in alleviating neuromuscular function decline in ALS
MG53 在缓解 ALS 神经肌肉功能衰退中的多方面作用
  • 批准号:
    10681888
  • 财政年份:
    2023
  • 资助金额:
    $ 7.31万
  • 项目类别:
MG53 function in muscle aging
MG53在肌肉衰老中的作用
  • 批准号:
    10442137
  • 财政年份:
    2022
  • 资助金额:
    $ 7.31万
  • 项目类别:
MG53 function in muscle aging
MG53在肌肉衰老中的作用
  • 批准号:
    10705606
  • 财政年份:
    2022
  • 资助金额:
    $ 7.31万
  • 项目类别:
Mitigating neuroinflammation and enhancing neuronal integrity in Alzheimer's disease
减轻阿尔茨海默病的神经炎症并增强神经元完整性
  • 批准号:
    10707976
  • 财政年份:
    2022
  • 资助金额:
    $ 7.31万
  • 项目类别:
Ca signaling cross-talk from SR to mitochondria in heart muscle
Ca 信号从 SR 到心肌线粒体的串扰
  • 批准号:
    9764466
  • 财政年份:
    2018
  • 资助金额:
    $ 7.31万
  • 项目类别:
Myokine function of MG53 in muscle injury-repair and regeneration
MG53在肌肉损伤修复和再生中的肌因子功能
  • 批准号:
    9924247
  • 财政年份:
    2017
  • 资助金额:
    $ 7.31万
  • 项目类别:
MG53-mediated membrane repair in muscle physiology and disease
MG53 介导的肌肉生理学和疾病中的膜修复
  • 批准号:
    9103694
  • 财政年份:
    2016
  • 资助金额:
    $ 7.31万
  • 项目类别:
MG53-mediated membrane repair in muscle physiology and disease
MG53 介导的肌肉生理学和疾病中的膜修复
  • 批准号:
    9770556
  • 财政年份:
    2016
  • 资助金额:
    $ 7.31万
  • 项目类别:
Targeting cell membrane repair for treatment of acute kidney injury
靶向细胞膜修复治疗急性肾损伤
  • 批准号:
    9102545
  • 财政年份:
    2016
  • 资助金额:
    $ 7.31万
  • 项目类别:
MG53-Mediated Membrane Repair in Muscle Physiology and Disease
MG53 介导的肌肉生理学和疾病中的膜修复
  • 批准号:
    8574275
  • 财政年份:
    2011
  • 资助金额:
    $ 7.31万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 7.31万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了